Tyra Biosciences Inc. (TYRA)
9.08
0.16 (1.79%)
At close: Apr 21, 2025, 3:59 PM
8.80
-3.08%
Pre-market: Apr 22, 2025, 04:14 AM EDT
1.79% (1D)
| Bid | 6.8 |
| Market Cap | 460.81M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -86.48M |
| EPS (ttm) | -1.51 |
| PE Ratio (ttm) | -6.01 |
| Forward PE | -3.95 |
| Analyst | Buy |
| Ask | 10 |
| Volume | 187,512 |
| Avg. Volume (20D) | 312,370 |
| Open | 7.67 |
| Previous Close | 8.92 |
| Day's Range | 8.45 - 9.16 |
| 52-Week Range | 6.42 - 29.60 |
| Beta | 1.19 |
About TYRA
Tyra Biosciences, Inc., a preclinical-stage biopharmaceutical company, focuses on developing therapies to overcome tumor resistance and enhance outcomes for patients with cancer. Its lead product candidate is TYRA-300, a selective inhibitor of fibroblast growth factor receptor (FGFR)3 for the treatment of muscle invasive bladder cancer. The company is also developing programs targeting FGFR2- intrahepatic cholangiocarcinoma,FGFR3-related achondro...
Industry Biotechnology
Sector Healthcare
IPO Date Sep 15, 2021
Employees 60
Stock Exchange NASDAQ
Ticker Symbol TYRA
Website https://www.tyra.bio
Analyst Forecast
According to 6 analyst ratings, the average rating for TYRA stock is "Buy." The 12-month stock price forecast is $30.5, which is an increase of 235.90% from the latest price.
Stock Forecasts5 months ago
-23.35%
Tyra Biosciences shares are trading lower. The com...
Unlock content with
Pro Subscription
